Key takeaways
- • Frequency: Uncommon but serious — 1.5-2.6% in trials.
- • Trial reference: STEP-1 (semaglutide) (1.5-2.6%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Rapid weight loss (>1-2 lbs/week) increases cholesterol concentration in bile, raising gallstone risk. GLP-1 medications also slow gallbladder emptying directly, compounding the effect.
How to manage it
- Aim for steady weight loss (~1-2 lbs/week, not faster) — slower loss reduces gallstone risk
- Hit fiber target (25-30g/day) — reduces cholesterol reabsorption
- Maintain healthy fat intake (avoid extreme low-fat diet — paradoxically increases stone risk)
- Stay hydrated
- If history of gallstones, discuss with prescriber before starting GLP-1
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Severe upper-right-abdomen pain (gallbladder colic)
- • Pain radiating to right shoulder blade
- • Pain after fatty meals
- • Fever + abdominal pain (possible cholecystitis — emergency)
- • Yellowing of skin or eyes (jaundice — bile duct obstruction)
Drug-specific notes
- Wegovy: Cholelithiasis ~1.6% (STEP-1) — higher than placebo
- Zepbound: Cholelithiasis ~2.0% (SURMOUNT-1)
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)